ArticleFrontiers in veterinary science2016
Pharmacokinetic/Pharmacodynamic Profiles of Tiamulin in an Experimental Intratracheal Infection Model of Mycoplasma gallisepticum.
Article in Frontiers in veterinary science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- PK/PD Modeling of a Novel Pleuromutilin Derivative Pleuro2-4 against Mycoplasma gallisepticum in Chicks.Journal of agricultural and food chemistry · 2026Article
- Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative APTM against Mycoplasma gallisepticum.Poultry science · 2026Article
- Highlight on the synergistic effect of different microemulsion formulations on the virulence determinants of multi-resistant Mycoplasma gallisepticum recovered from poultry.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Exploration of Cytochrome P450-Related Interactions between Aflatoxin B1 and Tiamulin in Broiler Chickens.Toxins · 2024Article
- Pharmacokinetic/pharmacodynamic integration of amphenmulin: a novel pleuromutilin derivative againstMicrobiology spectrum · 2024Article
- The novel pleuromutilin derivative 22-((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity bothFrontiers in pharmacology · 2024Article
- Pharmacokinetics and antibacterial activity of tiamulin after single and multiple oral administrations in geese.Veterinary and animal science · 2023Article
- Methylsulfonylmethane ameliorates inflammation via NF-κB and ERK/JNK-MAPK signaling pathway in chicken trachea and HD11 cells during Mycoplasma gallisepticum infection.Poultry science · 2022Article
- Rational Use of Danofloxacin for Treatment ofAntibiotics (Basel, Switzerland) · 2022Article
- Antimicrobial prescribing guidelines for poultry.Australian veterinary journal · 2021Article
- Temperature-Dependent Residue Depletion Regularities of Tiamulin in Nile Tilapia (Frontiers in veterinary science · 2021Article
- Detection and antibiotic resistance ofVeterinary world · 2020Article
- Tissue Residues and Pharmacokinetic/Pharmacodynamic Modeling of Tiamulin AgainstFrontiers in veterinary science · 2020Article
- Mycoplasma contamination affects cell characteristics and decreases the sensitivity of BV2 microglia to LPS stimulation.Cytotechnology · 2019Article
- A Validated HPLC-MS/MS Assay for 14-Molecules (Basel, Switzerland) · 2019Article
- Combination Therapy Strategies Against Multiple-ResistantFrontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma gallisepticum is the most important pathogen in poultry among four pathogenic Mycoplasma species. Tiamulin is a pleuromutilin antibiotic that shows a great activity against M. gallisepticum and has been approved for use in veterinary medicine particularly for poultry. However, the pharmacokinetic/pharmacodynamics (PK/PD) profiles of tiamulin against M. gallisepticum are not well understood. Therefore, in the current studies, we investigated the in vivo PK/PD profiles of tiamulin using a well-established experimental intratracheal infection model of M. gallisepticum. The efficacy of tiamulin against M. gallisepticum was studied in 8-day-old chickens after intramuscular (i.m.) administration at 10 doses between 0-80 mg/kg. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to evaluate the PK parameters of tiamulin following i.m. administration at doses of 5, 40, and 80 mg/kg in Mycoplasma gallisepticum-infected neutropenic chickens. Real-time PCR (RT-PCR) was used for quantitative detection of M. gallisepticum. The MIC of tiamulin against M. gallisepticum strain S6 was 0.03 μg/mL. The PK/PD index, AUC24h/MIC, correlated well with the in vivo antibacterial efficacy. The in vivo data suggest that animal dosage regimens should supply AUC24h/MIC of tiamulin of 382.68 h for 2 log10 ccu equivalents M. gallisepticum reduction. To attain that goal, the administered dose is expected to be 45 mg/kg b.w. for treatment of M. gallisepticum infection with an MIC90 of 0.03 μg/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.